Bioheng
Washington, District of Columbia, United States
Jan Davidson-Moncada, M.D., Ph.D., currently serves as Chief Medical Officer (CMO) at Bioheng Biotech. Bioheng is developing allogeneic CAR-T therapy for the treatment of malignancy and auto-immune disease. Current position involved development and leading global clinical and translational research for all product in the pipeline. Prior to joining Bioheng, I served as CMO at Wugen, Inc. Wugen, is a clinical-stage biotechnology company developing a pipeline of off-the-shelf memory natural killer (NK) and CAR T-cell therapies to treat a broad range of hematological and solid tumor malignancies.
Prior to joining Wugen, Jan served as Senior Director of Clinical Research at MacroGenics, Inc. where he led immuno-oncology clinical development and translational research programs for flotetuzumab, a CD123 x CD3 bispecific DART® protein in acute myeloid leukemia; MGD007, a gpA33 x CD3 DART in colorectal cancer; and margetuximab, an FC-optimized anti-HER2 monoclonal antibody evaluated in combination with pembrolizumab in advanced gastric cancer.
Jan served as Attending Physician at Walter Reed National Military Medical Center and NHLBI Bone Marrow Transplant Service. During this time he also served as Staff Clinician and Principal Investigator at the Center for Human Immunology. He received his MBBS and Ph.D. at University of College London, and a Master’s in clinic clinical and translational Investigation from Rockefeller University.
Monday, October 27, 2025
10:30 AM - 12:30 PM Central Time
Disclosure(s): bioheng: Employee (Ongoing)
Tuesday, October 28, 2025
10:30 AM - 12:30 PM Central Time
Disclosure(s): bioheng: Employee (Ongoing)
